Search results
15 Results for 'Adeno-Associated Virus (AAV)'
- Technologies (2)
- Collaborations (0)
- Team (0)
- News (10)
- Pages (0)
- Multimedia (2)
- Publications (0)
- Jobs (0)
- Events (1)
Technologies 2
-
MRBL: Next-Generation Gene Therapy for Molecular Skin Rejuvenation
The next-generation gene therapy for molecular skin rejuvenation combines a comprehensive target gene prediction with a novel transdermal delivery approach for therapeutic adenovirus-associated viruses. The platform targets monogenic disease indications in the skin, and extends the same targets to the treatment of common skin aging conditions. -
Synthetic AAV Capsids for Advanced Gene Therapy
The protein shell (capsid) of Adeno-associated viruses (AAV) are presently the most promising delivery vehicles for various in vivo gene therapies. AAVs are non-pathogenic and, through past engineering efforts, have become safe due to their inability to integrate into and damage the genome of target cells. Rather, the delivered DNA containing a therapeutic gene of...
News 10
Multimedia 2
-
Video/AnimationImproving Canine HealthspanA Wyss Institute technology that can treat multiple age-related diseases is now being developed by Rejuvenate Bio into a treatment for mitral valve disease and other deadly conditions in dogs, with the goal of helping man’s best friend live longer, healthier lives. Credit: Wyss Institute at Harvard University
-
Video/AnimationAAV Capsid EngineeringWyss researchers have created a high-throughput platform to generate an Adeno-associated virus 2 (AAV2) library containing 200,000 variants, each carrying a distinct mutation in the virus capsid protein. Their analysis identified capsid changes that enhanced “homing” potential to specific organs in mice and virus viability, as well as a new protein hidden in the capsid-encoding...